当前位置： SCI文献检索 > EUROPEAN JOURNAL OF OPHTHALMOLOGY期刊下所有文献 > Timogel® vs timolol 0.5% ophthalmic solution: efficacy, safety, and acceptance.

Timogel® vs timolol 0.5% ophthalmic solution: efficacy, safety, and acceptance.

Abstract：

PURPOSE:To evaluate the efficacy, safety, and tolerability of Timogel® preservative-free once daily compared to timolol 0.5% ophthalmic solution bid in patients with ocular hypertension (OHT) and patients with primary open-angle glaucoma (POAG). METHODS:A total of 75 patients with OHT and patients with POAG treated with timolol 0.5% bid with intraocular pressure (IOP) ≤ 21 mmHg were enrolled. They underwent complete ophthalmologic examination, IOP measurements (at trough and daytime curve), evaluation of side effects, Schirmer test, break-up time [BUT], blood pressure, heart rate, ocular diastolic perfusion pressure measurements, and acceptance (Comparison of Ophthalmic Medications for Tolerability). Patients switched to Timogel® and were re-evaluated 3 months later. The analysis of variance and the Pearson Chi2 tests were used to test differences between the treatments. RESULTS:Intraocular pressure reduction at trough was 23.6% with timolol 0.5% and 22.3% with Timogel®. No statistical differences were observed in IOP values at trough and in the daytime curve between the 2 treatments. Local and systemic side effects were less frequent with Timogel® (hazard ratio: p<0.05). Patients demonstrated a significant improvement of Schirmer test and BUT (p<0.05) and a reduction of dryness and foreign body sensation (42.6% vs 15.4%; p<0.01) after switching to Timogel®. Mild and short-lasting blurred vision after Timogel® instillation occurred in about 18.5% of patients. A total of 82% of patients were satisfied or very satisfied with Timogel® vs 61% with previous treatment (p<0.01). CONCLUSIONS:Timogel® preservative-free dosed once every morning has a 24-hour hypotensive effect with a better safety profile than timolol 0.5% bid and it is well-accepted by patients. The once-daily dosing improved acceptance and compliance.

journal_name

Eur J Ophthalmol

journal_title

European journal of ophthalmology

authors

Rolle T,Curto D,Alovisi C,Franzone M,Brogliatti B,Grignolo FM

doi

10.5301/ejo.5000006

subject

Has Abstract

pub_date

2012-01-01 00:00:00

pages

28-33

issue

eissn

1120-6721

issn

1724-6016

pii

5FF14743-48B0-4ED7-A6C4-84A4A8847F73

journal_volume

pub_type

杂志文章

在线工具

Timogel® vs timolol 0.5% ophthalmic solution: efficacy, safety, and acceptance.